The primary aim is to evaluate impacts of a behavioral intervention called "Mindfulness-Based Blood Pressure Reduction" (MB-BP) vs. enhanced usual care control on systolic blood pressure at 6 months, via a randomized controlled trial.
Effects of mindfulness interventions customized for prehypertensive/hypertensive patients are poorly understood. Until methodologically rigorous studies to evaluate customized interventions for hypertension are performed, it will be unknown whether the observed preliminary effects of general mindfulness interventions on blood pressure reduction could be much more effective with a tailored approach. Consequently, this study proposes to conduct a behavioral intervention study to evaluate whether Mindfulness-Based Stress Reduction (MBSR) customized to prehypertensive and hypertensive patients has the potential to provide clinically relevant reductions in blood pressure. This customized intervention is called Mindfulness-Based Blood Pressure Reduction (MB-BP). The study follows the NIH Stage Model for Behavioral Intervention Development, where targets likely proximally affected by the intervention are identified, that should also have effect on the longer-term outcomes (e.g. blood pressure, mortality). The selected targets, consistent with theoretical frameworks and early evidence how mindfulness interventions could influence mental and physical health outcomes, are measures of self-regulation including (1) attention control (specifically the Sustained Attention Response Task and Mindful Attention Awareness Scale), (2) emotion regulation (specifically the Pittsburgh Stress Battery and the Perceived Stress Scale), and (3) self-awareness (specifically the Heart Beat Detection Task and Multidimensional Assessment of Interoceptive Awareness). Based on the degree of target engagement, MB-BP can be further customized to better engage with the targets as needed. Specific aims are as follows. The primary aim is to evaluate impacts of MB-BP vs. enhanced usual care control on systolic blood pressure at 6 months. Follow-up time periods include 10 weeks and 6 months. Secondary aims include evaluating impacts of MB-BP vs. enhanced usual care control on self-regulation mechanistic target engagement, including (1) attention control (specifically the Sustained Attention Response Task and Mindful Attention Awareness Scale), (2) emotion regulation (specifically the Pittsburgh Stress Battery and the Perceived Stress Scale), and (3) self-awareness (specifically the Heart Beat Detection Task and Multidimensional Assessment of Interoceptive Awareness). Further secondary aims include evaluating impacts of MB-BP vs. active control on medical regimen adherence, including (1) physical activity, (2) Dietary Approaches to Stop Hypertension (DASH)-consistent diet, (3) alcohol consumption, (4) body mass index, and (5) antihypertensive medication use and adherence. Secondary blood pressure outcomes include diastolic blood pressure. This study is a randomized controlled trial, with blinding of staff performing participant assessments and data analysts performing statistical analyses.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
82
MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions and a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Homework consists of practicing skills for ≥45 min/day, 6 days/week. Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified, if not already overseen for uncontrolled hypertension; those without a physician are worked with to provide access within health insurance constraints.
Control group participants receive an educational brochure from American Heart Association entitled "Understanding and Controlling Your High Blood Pressure Brochure" (product code 50-1639). Every participant is provided with a validated home blood pressure monitor (Omron, Model PB786N), that as an evidence-based approach to lower blood pressure, would be considered "enhanced usual care" at this time. All participants who have uncontrolled hypertension (blood pressure \>140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for uncontrolled hypertension. For participants with uncontrolled hypertension who do not have a physician, we work participants to provide access within constraints of their health insurance.
Brown University School of Public Health
Providence, Rhode Island, United States
Systolic blood pressure
Directly assessed as mean of second and third blood pressure readings
Time frame: 6 month follow-up
Dietary Approaches to Stop Hypertension-consistent diet
Self-report via Willet Food Frequency Questionnaire
Time frame: 6 month follow-up
Sustained Attention to Response Task (SART)
Behavioral measure of attention control
Time frame: 6 month follow-up
Mindful Attention Awareness Scale (MAAS)
Self-report measure of attention control and mindfulness
Time frame: 6 month follow-up
Pittsburgh Stress Battery
Behavioral measure of stress reactivity
Time frame: 6 month follow-up
Perceived Stress Scale
Self-report measure of perceived stress
Time frame: 6 month follow-up
Heartbeat Detection Task
Behavioral measure of self-awareness
Time frame: 6 month follow-up
Multidimensional Assessment of Interoceptive Awareness (MAIA)
Self-report measure of self-awareness
Time frame: 6 month follow-up
Physical Activity - self report
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Self-report via International Physical Activity Questionnaire (IPAQ)
Time frame: 6 month follow-up
Physical Activity - step count
Directly assessed via FitBit step count
Time frame: 6 month follow-up
Alcohol consumption
Self-report via Willet Food Frequency Questionnaire
Time frame: 6 month follow-up
Body Mass Index
Directly assessed as weight (kg) per height (m) squared, using a validated stadiometer to assess height, and validated scale to measure weight.
Time frame: 6 month follow-up
Antihypertensive medication adherence
Directly assessed via eCAP medication adherence devices (Information Mediary Corp., Ottawa, ON, Canada). Please note that eCAP is the device name, and not an acronym.
Time frame: 6 month follow-up
Antihypertensive medication use
Directly assessed via medication bottle labels that participants bring to clinic assessments
Time frame: 6 month follow-up
Diastolic blood pressure
Directly assessed as mean of second and third readings
Time frame: 6 month follow-up